Analyst Reco. Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
25.58 ^USD	+0.06%		+0.27%	+58.59%

Jun. 03	Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor At the 2024 Asco Annual Meeting and Online Publication in the Lancet	CI
May. 10	Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26	Apr. 30	MT
Leerink Downgrades Deciphera Pharmaceuticals to Market Perform, Price Target at $25.60	Apr. 30	MT
JMP Downgrades Deciphera Pharmaceuticals to Market Perform	Apr. 30	MT
JonesTrading Downgrades Deciphera Pharmaceuticals to Hold From Buy, Adjusts Price Target to $25.60 From $16	Apr. 29	MT
Jefferies Downgrades Deciphera Pharmaceuticals to Hold From Buy, Trims Price Target to $25.60 From $26	Apr. 29	MT
North American Morning Briefing : Rate Doubts Keep -2-	Feb. 06	DJ
Deciphera Says Long-Term Data Show 'Similar' Overall Survival Rates for Qinlock, Sunitinib	Jan. 18	MT
HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $30 From $25, Keeps Buy Rating	23-10-31	MT
JonesTrading Upgrades Deciphera Pharmaceuticals to Buy From Hold, $16 Price Target	23-10-31	MT
Piper Sandler Upgrades Deciphera Pharmaceuticals to Overweight From Neutral, Raises Price Target to $23 From $18	23-10-30	MT
Stifel Upgrades Deciphera Pharmaceuticals to Buy From Hold, Adjusts Price Target to $20 From $14	23-08-10	MT
HC Wainwright Reiterates Deciphera Pharmaceuticals at Buy With $25 Price Target	23-02-08	MT
SVB Securities Adjusts Deciphera Pharmaceuticals Price Target to $30 From $28, Maintains Outperform Rating	23-02-07	MT
Cowen Adjusts Price Target on Deciphera Pharmaceuticals to $30 From $25, Maintains Outperform Rating	23-01-25	MT
JonesTrading Upgrades Deciphera Pharmaceuticals to Hold From Sell	23-01-06	MT
SVB Securities Raises Price Target on Deciphera Pharmaceuticals to $28 From $25, Keeps Outperform Rating	23-01-04	MT
Barclays Adjusts Deciphera Pharmaceuticals Price Target to $9 From $8, Maintains Underweight Rating	23-01-04	MT
Guggenheim Upgrades Deciphera Pharmaceuticals to Buy From Neutral, Price Target is $22	23-01-04	MT
Stifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Hold Rating	22-09-27	MT
Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains Neutral Rating	22-09-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Analyst Reco.

Filters